Non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins elicits anti-tumor immunity in mice.
- Author:
Wei-feng LUO
1
;
Li-qun HAN
;
Jiao REN
;
Hou-wen TIAN
;
Zhen-hua LU
;
Li ZHAO
;
Shu-yan GU
;
Li RUAN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Cancer Vaccines; Cells, Cultured; Female; Genetic Vectors; Immunotherapy; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; immunology; therapy; Oncogene Proteins, Viral; genetics; Papillomaviridae; genetics; Papillomavirus E7 Proteins; Recombination, Genetic; Repressor Proteins; genetics; T-Lymphocytes, Cytotoxic; immunology; Vaccinia virus; genetics; Viral Vaccines
- From: Chinese Journal of Oncology 2003;25(4):335-339
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the anti-tumor immunity of the non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins.
METHODSC57BL/6 mice were immunized by non-replicating recombinant vaccinia virus (NTVJmE6E7), and then specific CTLs were determined. Immune protection effects were evaluated by challenges of different doses of TC-1 tumor cells. Immunotherapeutic effects in form of recurrence were evaluated on the tumor-removed mice.
RESULTSMice immunized by NTVJmE6E7 could generate TC-1 cell specific cytotoxic T lymphocyte (CTL). Mice boosted with NTVJmE6E7 could tolerate the challenge of 1 x 10(4) TC-1 cells. NTVJmE6E7 could effectively prevent the tumor recurrence in the tumor-removed mice.
CONCLUSIONNTVJmE6E7 can be taken as a candidate of therapeutic vaccine for HPV-associated tumors and their precursor lesions.
